Hims & Hers Health (NYSE:HIMS) Insider Sells $694,324.50 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Michael Chi sold 13,749 shares of Hims & Hers Health stock in a transaction on Wednesday, September 17th. The shares were sold at an average price of $50.50, for a total value of $694,324.50. Following the completion of the sale, the insider directly owned 297,139 shares of the company’s stock, valued at $15,005,519.50. The trade was a 4.42% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Michael Chi also recently made the following trade(s):

• On Monday, September 15th, Michael Chi sold 4,150 shares of Hims & Hers Health stock. The shares were sold at an average price of $56.00, for a total value of $232,400.00.
• On Thursday, July 24th, Michael Chi sold 2,100 shares of Hims & Hers Health stock. The shares were sold at an average price of $57.52, for a total value of $120,792.00.
• On Wednesday, July 23rd, Michael Chi sold 13,750 shares of Hims & Hers Health stock. The shares were sold at an average price of $56.00, for a total value of $770,000.00.

Hims & Hers Health Trading Up 2.7%

Shares of NYSE HIMS opened at $57.74 on Friday. Hims & Hers Health, Inc. has a twelve month low of $15.73 and a twelve month high of $72.98. The company has a current ratio of 4.98, a quick ratio of 4.46 and a debt-to-equity ratio of 1.72. The stock has a fifty day simple moving average of $50.71 and a 200-day simple moving average of $45.66. The stock has a market capitalization of $13.05 billion, a PE ratio of 72.18, a PEG ratio of 3.80 and a beta of 2.14.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, August 4th. The company reported $0.17 earnings per share for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.01). Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The firm had revenue of $544.83 million during the quarter, compared to analyst estimates of $550.06 million. During the same period in the previous year, the firm posted $0.06 earnings per share. The company’s quarterly revenue was up 72.6% compared to the same quarter last year. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, equities analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Wall Street Analysts Forecast Growth

HIMS has been the subject of several analyst reports. UBS Group set a $30.00 target price on Hims & Hers Health in a research note on Monday, June 23rd. Morgan Stanley reaffirmed an “equal weight” rating and set a $40.00 price target on shares of Hims & Hers Health in a report on Wednesday, June 11th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $68.00 price target on shares of Hims & Hers Health in a report on Friday, September 12th. Wall Street Zen downgraded Hims & Hers Health from a “buy” rating to a “hold” rating in a report on Monday, July 28th. Finally, Zacks Research downgraded Hims & Hers Health from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 19th. Two analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Reduce” and a consensus target price of $38.92.

Institutional Trading of Hims & Hers Health

Several large investors have recently bought and sold shares of the company. Geode Capital Management LLC grew its holdings in Hims & Hers Health by 1.5% in the second quarter. Geode Capital Management LLC now owns 4,746,081 shares of the company’s stock valued at $236,622,000 after purchasing an additional 71,593 shares during the last quarter. Invesco Ltd. grew its holdings in Hims & Hers Health by 502.2% in the second quarter. Invesco Ltd. now owns 2,552,405 shares of the company’s stock valued at $127,237,000 after purchasing an additional 2,128,587 shares during the last quarter. Northern Trust Corp grew its holdings in Hims & Hers Health by 19.5% in the first quarter. Northern Trust Corp now owns 2,435,512 shares of the company’s stock valued at $71,969,000 after purchasing an additional 397,310 shares during the last quarter. Yong Rong HK Asset Management Ltd grew its holdings in Hims & Hers Health by 41.2% in the first quarter. Yong Rong HK Asset Management Ltd now owns 2,400,000 shares of the company’s stock valued at $70,920,000 after purchasing an additional 700,100 shares during the last quarter. Finally, Nuveen LLC acquired a new stake in Hims & Hers Health in the first quarter valued at $58,403,000. Institutional investors and hedge funds own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.